From Yahoo Finance: 2025-06-15 05:26:00

Jim Cramer recently discussed BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and expressed skepticism about the company’s orphan drug model, stating, “I don’t think it works now.” Despite this, in 2023, Cramer advised holding onto the stock, but since then, BMRN has dropped more than 49%.

BioMarin is a biotech company specializing in genetic research-based treatments with a history of innovation. While some see potential in investing in BMRN, others believe AI stocks offer greater upside with less risk. For those interested in undervalued AI stocks, a report on the best short-term AI stock is available.

For more insights on stock trends, check out “The Best and Worst Dow Stocks for the Next 12 Months” and “10 Unstoppable Stocks That Could Double Your Money.” Disclosure: None.

Read more: “I Don’t Think It Works Now”